Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com 

Moderna stands to benefit from weeks of media fear over hantavirus because it has an early-stage vaccine. With an incubation period of about eight weeks, the coverage should persist even though the threat looks overblown, making this a very risky, high-upside bet to exit before sentiment turns. In a clip shared by @FurkanGozukara, Dr. Pierre Kory notes over 100,000 hantavirus articles were published globally in days. x.com 

Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com 

Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna looks like a risky hold over the weekend after a rough week and a potential secondary-offering overhang. x.com 

Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.com 

Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com 

Moderna is a stock to bet against. x.com 

Moderna is worth roughly $190-215 a share on a probability-weighted outcome tree, above the $157 price after its melanoma vaccine readout. Failure implies $75-85, melanoma-only $125-160, positive Phase 3 lung data $250-400, and broad cancer vaccination far more. The market is more skeptical on lung, and that readout decides the trade. With about 50M shares short, a squeeze could hit $400 before a return to a $120-190 range. Most outcomes sit at or below the price, so defined risk is warranted. … Show more